Ramya C Valiveru1, Gaurav Agarwal2, Vinita Agrawal3, Sabaretnam Mayilvaganan1, Gyan Chand1, Anjali Mishra1, Amit Agarwal1, Saroj Kanta Mishra1, Eesh Bhatia4. 1. Department of Endocrine & Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, UP, 226014, India. 2. Department of Endocrine & Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, UP, 226014, India. gaurav@sgpgi.ac.in. 3. Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, UP, 226014, India. 4. Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, UP, 226014, India.
Abstract
BACKGROUND: Aggressiveness of hereditary medullary thyroid carcinoma (hMTC) has been conventionally described to correlate with American Thyroid Association (ATA) risk groups based on RET mutations. Recent evidence increasingly contradicts this notion. We studied the RET genotype and its correlation with disease phenotype and survival outcomes in a cohort of hMTC patients. METHODS: In a retrospective cohort of 55 hMTC patients from 23 families treated at a north Indian tertiary care institute over 15-years, RET genotype was correlated with disease phenotype (clinical, biochemical, and pathological attributes) and outcomes in terms of biochemical cure (normalization of serum calcitonin), structural cure, overall survival (OS) and disease specific survival (DSS). RESULTS: Forty-nine patients had Multiple Endocrine Neoplasia (MEN)-type 2A syndrome, 02 had MEN-2B, and 4 had familial MTC. Two patients belonged to highest ATA risk, 41 to high-risk, and 12 to moderate risk categories. Age of the patients or stage of disease at presentation did not differ significantly between the ATA risk groups. Though the baseline serum calcitonin was significantly higher in highest risk category, the biochemical cure rates were not significantly different. At a median follow up of 48 months (Inter-quartile range 18-84, range 12-192) structural cure rates in ATA moderate and high risk groups were significantly higher than highest risk group (p = 0.04). No significant difference in OS between the three ATA groups of hMTC among the patients who underwent surgical treatment was observed (p = 0.098). CONCLUSIONS: The ATA moderate and high risk groups have better structural cure rates compared to ATA highest risk group. The biochemical cure and overall survival rates did not significantly differ between ATA risk-groups, and were impacted by the disease stage at presentation. The current ATA risk-groups do not reliably predict the outcomes in terms of biochemical cure and survival in hMTC patients.
BACKGROUND:Aggressiveness of hereditary medullary thyroid carcinoma (hMTC) has been conventionally described to correlate with American Thyroid Association (ATA) risk groups based on RET mutations. Recent evidence increasingly contradicts this notion. We studied the RET genotype and its correlation with disease phenotype and survival outcomes in a cohort of hMTC patients. METHODS: In a retrospective cohort of 55 hMTC patients from 23 families treated at a north Indian tertiary care institute over 15-years, RET genotype was correlated with disease phenotype (clinical, biochemical, and pathological attributes) and outcomes in terms of biochemical cure (normalization of serum calcitonin), structural cure, overall survival (OS) and disease specific survival (DSS). RESULTS: Forty-nine patients had Multiple Endocrine Neoplasia (MEN)-type 2A syndrome, 02 had MEN-2B, and 4 had familial MTC. Two patients belonged to highest ATA risk, 41 to high-risk, and 12 to moderate risk categories. Age of the patients or stage of disease at presentation did not differ significantly between the ATA risk groups. Though the baseline serum calcitonin was significantly higher in highest risk category, the biochemical cure rates were not significantly different. At a median follow up of 48 months (Inter-quartile range 18-84, range 12-192) structural cure rates in ATA moderate and high risk groups were significantly higher than highest risk group (p = 0.04). No significant difference in OS between the three ATA groups of hMTC among the patients who underwent surgical treatment was observed (p = 0.098). CONCLUSIONS: The ATA moderate and high risk groups have better structural cure rates compared to ATA highest risk group. The biochemical cure and overall survival rates did not significantly differ between ATA risk-groups, and were impacted by the disease stage at presentation. The current ATA risk-groups do not reliably predict the outcomes in terms of biochemical cure and survival in hMTC patients.
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Kristin L Long; Carol Etzel; Thereasa Rich; Samuel Hyde; Nancy D Perrier; Paul H Graham; Jeffrey E Lee; Mimi I Hu; Gilbert J Cote; Robert Gagel; Elizabeth G Grubbs Journal: Fam Cancer Date: 2017-04 Impact factor: 2.375
Authors: Rachel K Voss; Lei Feng; Jeffrey E Lee; Nancy D Perrier; Paul H Graham; Samuel M Hyde; Frances Nieves-Munoz; Maria E Cabanillas; Steven G Waguespack; Gilbert J Cote; Robert F Gagel; Elizabeth G Grubbs Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Maria A Kouvaraki; Suzanne E Shapiro; Nancy D Perrier; Gilbert J Cote; Robert F Gagel; Ana O Hoff; Steven I Sherman; Jeffrey E Lee; Douglas B Evans Journal: Thyroid Date: 2005-06 Impact factor: 6.568
Authors: Philip M Spanheimer; Ian Ganly; Joanne Chou; Marinela Capanu; Ronald A Ghossein; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Brian R Untch Journal: Ann Surg Oncol Date: 2019-09-23 Impact factor: 5.344
Authors: Rui M B Maciel; Cleber P Camacho; Lígia V M Assumpção; Natassia E Bufalo; André L Carvalho; Gisah A de Carvalho; Luciana A Castroneves; Francisco M de Castro; Lucieli Ceolin; Janete M Cerutti; Rossana Corbo; Tânia M B L Ferraz; Carla V Ferreira; M Inez C França; Henrique C R Galvão; Fausto Germano-Neto; Hans Graf; Alexander A L Jorge; Ilda S Kunii; Márcio W Lauria; Vera L G Leal; Susan C Lindsey; Delmar M Lourenço; Léa M Z Maciel; Patrícia K R Magalhães; João R M Martins; M Cecília Martins-Costa; Gláucia M F S Mazeto; Anelise I Impellizzeri; Célia R Nogueira; Edenir I Palmero; Cencita H C N Pessoa; Bibiana Prada; Débora R Siqueira; Maria Sharmila A Sousa; Rodrigo A Toledo; Flávia O F Valente; Fernanda Vaisman; Laura S Ward; Shana S Weber; Rita V Weiss; Ji H Yang; Magnus R Dias-da-Silva; Ana O Hoff; Sergio P A Toledo; Ana L Maia Journal: Endocr Connect Date: 2019-03-01 Impact factor: 3.335